Clinical Trial

Whole Versus Partial Gland Boost During Prostate SBRT

Not Yet Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
This phase 2/3 randomized trial evaluates whether dose escalation to the dominant intra-prostatic lesion (DIL) compared to whole gland dose escalation during prostate stereotactic body radiotherapy (SBRT) results in differences in genitourinary (GU) and gastrointestinal (GI) toxicities.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2026-04-30; most recent amendment 2026-06-25.
Trial Details
NCT Number NCT07574489
Lead Sponsor University of Nebraska
Conditions Prostate Cancer, Prostate Adenocarcinoma
Enrollment 186 participants
Start Date 2026-07-25
Primary Completion 2032-08-25 (estimated)
Study Completion 2035-08-25 (estimated)
Updated on ClinicalTrials.gov 2026-06-29